BridgeBio Pharma, Inc.（BBIO）财务数据BBIOBridgeBio Pharma, Inc.

Evaluating the bottom line, BridgeBio Pharma, Inc. maintains a gross margin of 93.83%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -43.94%, while the net margin is -63.97%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BBIO converts its operational activities into shareholder value.

In the context of the broader market, BBIO competes directly with industry leaders such as HALO and SMMT. With a market capitalization of $12.86B, it holds a significant position in the sector. When comparing efficiency, BBIO's gross margin of 93.83% stands against HALO's 77.40% and SMMT's N/A. Such benchmarking helps identify whether BridgeBio Pharma, Inc. is trading at a premium or discount relative to its financial performance.

BridgeBio has shown significant revenue growth, with Q2 2026 revenue at $243,676,000, up from $588,200 in Q4 2024. However, it continues to report substantial net losses, with a net income of -$152,216,000 in Q2 2026.